Reuters logo
BRIEF-Zymeworks announces license agreement with Johnson & Johnson Innovation
November 13, 2017 / 10:04 AM / 10 days ago

BRIEF-Zymeworks announces license agreement with Johnson & Johnson Innovation

Nov 13 (Reuters) - Zymeworks Inc

* Zymeworks announces license agreement with Johnson & Johnson Innovation to develop and commercialize next generation bispecific antibody therapeutics

* Says ‍US$50 million upfront license fee paid to Zymeworks for up to six bispecific programs​

* Says Zymeworks licenses azymetric and efect platforms to Janssen​

* Says ‍deal was facilitated by Johnson & Johnson Innovation​

* Says co is eligible to potentially receive up to $282 million in development & up to US$1.12 billion in commercial milestone payments, tiered royalties

* Says ‍Janssen also has option to develop two additional bispecific programs under agreement subject to a future option payment​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below